Filana Therapeutics (FLNA) Income towards Parent Company (2010 - 2026)

Filana Therapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$9.6 million for Q2 2026.

• In Q2 2026, Income towards Parent Company rose 79.02% year-over-year to -$9.6 million; the TTM figure through Jun 2026 stood at -$46.7 million (up 64.3% YoY), while the FY2025 annual figure was -$207.3 million, up 12.95% from the prior year.
• Income towards Parent Company for Q2 2026 stood at -$9.6 million, up from -$11.4 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$9.6 million in Q2 2026, with the low at -$61.6 million in Q2 2024.
• The 5-year median for Income towards Parent Company is -$22.0 million (2022), against an average of -$24.5 million.
• The sharpest annual moves came in 2022 and 2026: Income towards Parent Company slumped 371.72% in 2022, then surged 79.02% in 2026.
• Filana Therapeutics' Income towards Parent Company stood at -$19.8 million in 2022, then retreated by 16.5% to -$23.1 million in 2023, then fell by 28.39% to -$29.6 million in 2024, then jumped by 53.83% to -$13.7 million in 2025, then surged by 30.16% to -$9.6 million in 2026.
• Business Quant data shows FLNA's Income towards Parent Company at -$9.6 million in Q2 2026, -$11.4 million in Q1 2026, and -$13.7 million in Q4 2025.